The £400 million ($529 million) investment programme pledged as part of the new voluntary system of rebates paid by pharma companies in the UK has been announced and will focus mainly on su
The UK drugs regulator has approved Eisai and Biogen's Alzheimer's disease therapy Leqembi, shortly after an EU committee turned it down on the grounds that its modest efficacy did not outw
The Tony Blair Institute (TBI) has called for a digital health record (DHR) for everyone in the UK within five years to "ensure that the NHS is ready for the artificial intelligence era."
NICE has defended a trio of decisions on new therapies for multiple myeloma, which saw two drugs approved for restricted use in England and Wales and a third turned down altogether.
Vertex and CRISPR Therapeutics have won the backing of NICE for their gene-editing therapy Casgevy as a treatment for the blood disorder beta thalassaemia, a few months after turning it dow